Using nationally representative data, we found that for common physician-administered drugs, hospitals' cash prices are frequently lower than their median-and sometimes even their lowest-commercial negotiated prices.
A new Johns Hopkins analysis of 205,896 branded medication fills offers the first national look inside the prior authorization process — tracking how long patients wait, who gets approved, and who bears the cost.
The enactment of the Inflation Reduction Act (IRA) and the growth of state Prescription Drug Affordability Boards have raised important questions about how to improve drug affordability without curbing biopharmaceutical innovation
